* UK reports five cases of blood clots due to vaccines
* 11 million people have had AstraZeneca's vaccine in UK
* Medical regulator cautions on 4-day headache or bruising
* Benefits of the shot far outweigh possible risks, it says
(Adds reaction, detail)
By Alistair Smout
LONDON, March 18 (Reuters) - Britain's medicines regulator
said there had been five cases of a rare type of blood clot in
the brain among 11 million given AstraZeneca's COVID-19 vaccine
but said that it found the benefits of the shot far outweighed
any possible risks.
Concerns about reports of blood clots, along with low
platelet levels, have led to some European countries including
Germany to pause the rollout of the shot while the cases are
investigated by the European Medicines Agency (EMA), which is
set to announce its findings later in the day.
Britain's Medicines and Healthcare products Regulatory
Agency (MHRA) said that use of the vaccine should continue while
five reports were investigated, and one official said that the
rollout would likely continue even if a link was proved.
"There is no evidence that blood clots in veins is occurring
more than would be expected in the absence of vaccination, for
either vaccine," said June Raine, MHRA Chief Executive,
referring to AstraZeneca and Pfizer shots.
Raine said there had been a very small number of reports of
an extremely rare form of blood clot in the cerebral veins
(sinus vein thrombosis, or CSVT) occurring together with lowered
platelets soon after vaccination.
"Given the extremely rare rate of occurrence of these CSVT
events among the 11 million people vaccinated (with
AstraZeneca), and as a link to the vaccine is unproven, the
benefits of the vaccine in preventing COVID-19, with its
associated risk of hospitalisation and death, continue to
outweigh the risks of potential side effects," she said.
One of the reported cases was fatal, MHRA Vaccine Safety
Lead Philip Bryan said, adding that the cases were all among men
aged between 19 and 59.
NO PAUSE NECESSARY
The MHRA said anyone with a headache that lasts for more
than four days after vaccination, or bruising beyond the site of
vaccination after a few days, should seek medical attention.
The regulator said there was an ongoing review into "five UK
reports of a very rare and specific type of blood clot in the
cerebral veins (sinus vein thrombosis) occurring together with
lowered platelets (thrombocytopenia)".
Munir Pirmohamed, Chair of the Commission on Human
Medicines, in a statement suggested that even if a link between
the clots and the vaccine was established, it likely wouldn't
halt Britain's rollout.
"If we feel that there's causal link then we may need to
update the product information, but overall, I don't think that
would necessitate pause to any kind of vaccination programme,"
he told reporters in a briefing.
The EMA is investigating reports of 30 cases of unusual
blood disorders out of 5 million people who got the AstraZeneca
vaccine in the EU, and is focusing on blood clots in the head.
Stephen Evans, at London School of Hygiene and Tropical
Medicine, said that COVID-19 itself was associated with similar
symptoms, making causality hard to establish.
"A major problem is discerning whether there is a
possibility that this was caused by COVID-19," Evans told
Reuters.
"Exactly these sort of conditions have been seen in patients
with COVID-19 prior to the vaccines being available."
(Reporting by Alistair Smout and Guy Faulconbridge, additional
reporting by Kate Holton and Kate Kelland; Editing by Nick
Macfie)
Astrazeneca (AZN)
